ORCHID PHARMA LIMITED Fair Value
ORCHPHARMA · Healthcare · Current price ₹942.9
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹223 | 2% ROE fading to 12% over ~3 yrs, on ₹254 book |
| Relative P/E | ₹141 | EPS × 34.7 peer-median P/E |
| Graham floor | ₹152 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | ₹1,061 | Street consensus 12-month target price |
Is ORCHID PHARMA LIMITED undervalued?
DocStoX estimates the fair value of ORCHID PHARMA LIMITED at ₹345 per share, versus the current market price of ₹943. That puts the stock about -63.4% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 4 independent methods: Residual income (₹223), Relative P/E (₹141), Graham floor (₹152), Analyst target (₹1,061). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹141 (bear) to ₹345 (base) to ₹1,061 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on ORCHID PHARMA LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.